
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 1, 2010

UROPLASTY, INC.

(Exact name of registrant as specified in charter)

001-32632
(Commission File No.)

41-1719250
(IRS Employer Identification No.)

Minnesota
(State or other jurisdiction of incorporation or organization)

5420 Feltl Road
Minnetonka, Minnesota 55343
(Address of principal executive offices)

952-426-6140
(Registrant's telephone number, including area code)

Not Applicable
(Former Name and Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 of the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure

The following forward-looking statements are subject to risks and uncertainties. We may not meet the expectations set out below. In addition, we recommend that you carefully consider the risk factors described in our other SEC filings in evaluating us.

Publication of the Results of Clinical Trials. On March 1, 2010 we issued a press release announcing an expected publication, in the April 2010 print edition (e-published on February 22, 2010) of *The Journal of Urology*[®], reporting on the results of our SUmIT Trial, a 220-patient, multicenter, randomized, controlled, double-blind study that compared the effectiveness of percutaneous tibial nerve stimulation to a validated sham procedure.

On March 3, 2010 we issued a press release announcing an expected publication, in the April 2010 print edition (e-published on February 22, 2010) of *The Journal of Urology*[®], reporting on the results of a 24-month study that evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months.

Item 9.01. Financial Statements and Exhibits

(c) Exhibit (filed herewith)

- 99.1 Press Release dated March 1, 2010
- 99.2 Press Release dated March 3, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 4, 2010

UROPLASTY, INC.

By: /s/ Mahedi A. Jiwani
Mahedi A. Jiwani
Vice President, Chief Financial Officer and
Treasurer



<DOCUMENT>
<TYPE> EX-99.1
<FILENAME> c56766exv99w1.htm
<DESCRIPTION> EX-99.1
<TEXT>

NEWS RELEASE



SUmIT TRIAL RESULTS CLEARLY DEMONSTRATE THERAPEUTIC EFFECT OF PERCUTANEOUS TIBIAL NERVE STIMULATION

Urgent® PC was statistically superior to a validated sham procedure in a randomized, controlled, multicenter study

MINNEAPOLIS, MN, March 1, 2009 — Uroplasty, Inc. (NYSE: Amex UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results of the SUmIT Trial of its Urgent® PC Neuromodulation System that will be published in the April 2010 print edition of *THE JOURNAL OF UROLOGY*® and is now available on line. The Urgent PC System is a proprietary, minimally invasive, percutaneous tibial nerve stimulation (PTNS) device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder (OAB).

The pivotal SUmIT Trial was a 220-patient, multicenter, randomized, controlled, double-blind study. Patients and investigators reported statistically significant OAB symptom improvement compared to a validated sham procedure.

Highlights from the study include:

- 58.3% of PTNS patients considered their overall urinary symptoms moderately or markedly improved compared to only 21.9% of sham patients
- Statistically significant changes for PTNS patients included reduction in voiding frequency, urinary urge incontinence episodes, nighttime voids, urgency episodes and voids with moderate to severe volume, in addition to improvement in voiding volume and quality of life measures.
- Neither group reported any serious adverse events

“This important study is the first publication that demonstrates the effectiveness of PTNS compared to a validated sham procedure” said Dr. Kenneth Peters, lead investigator, and Chairman of the Department of Urology at Beaumont Hospital in Royal Oak, Michigan. “PTNS is a viable OAB treatment and its efficacy is irrefutably demonstrated. It is rare that a medical device is put through such rigorous testing, first comparing it to standard drug therapy as recently done in the OrBIT study and now demonstrating superiority to a sham procedure.”

Publication of the SUmIT Trial follows the publication in *The JOURNAL OF UROLOGY* of both the 12-week OrBIT (**O**ve ractive **B**ladder **I**nnovative **T**herapy) multi-center trial in September 2009 and the 12-month OrBIT long term results in January 2010. The 12-week results demonstrated that patients treated with PTNS had fewer significant side effects as well as

clinical improvements comparable to patients treated with a leading oral, extended-release OAB drug. The 12-month results demonstrated long term durability of the initial response to PTNS.

“We believe these results erase any doubt that PTNS provides real and measurable clinical results” said Dave Kaysen, President and Chief Executive Officer of Uroplasty, Inc. “Using a validated sham procedure provided a control usually seen in only the most rigorous pharmaceutical trials. We understand this type of study is rare in the medical device industry. We will use these results, along with previous peer-reviewed publications, to educate medical directors about PTNS effectiveness to establish reimbursement. The SUMiT Trial data is also a key component in our application to the American Medical Association considered at their February meeting for a unique CPT code for PTNS,” added Mr. Kaysen.

For more information about the Urgent[®] PC Neuromodulation System, please call 866-277-0466 or visit www.uroplasty.com.

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms. Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder.

We also offer Macroplastique[®] Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure

[E/O]

CRC: 61942
EDGAR 2

BOC C56766 799.01.03.00 0/1


you that we will timely obtain, or even succeed at all at obtaining, a unique CPT reimbursement code from the American Medical Association for Urgent PC treatments, that even if we obtain a unique CPT reimbursement code third-party payers will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses.

For Further Information:

Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and Treasurer, 952.426.6140	EVC Group Doug Sherk (Investors) 415.896.6820 Chris Gale (Media) 646.201.5431
--	---

###



<DOCUMENT>
<TYPE> EX-99.2
<FILENAME> c56766exv99w2.htm
<DESCRIPTION> EX-99.2
<TEXT>

Exhibit 99.2

NEWS RELEASE



NEW PUBLICATION HIGHLIGHTS 2-YEAR DURABILITY AND EFFECTIVENESS OF MACROPLASTIQUE®

MINNEAPOLIS, MN, March 3, 2010 — Uroplasty, Inc. (NYSE Amex: UPI) highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of *The Journal of Urology*®. The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.

“This study clearly demonstrates that Macroplastique provides a high level of long-term effectiveness,” said Uroplasty Chief Executive Officer and President David Kaysen. “The effectiveness means major improvements in quality of life for women who previously suffered from unwanted urinary leakage. While other urethral bulking agents may be absorbed into the body, potentially diminishing their clinical benefit, Macroplastique is composed of a permanent silicone elastomer that contributes to sustained, measurable patient improvement,” added Mr. Kaysen.

The study, titled “Durability of Urethral Bulking Agent Injection for Female Stress Urinary Incontinence: 2-Year Multicenter Study Results” followed 67 Macroplastique patients with successful outcomes at 12 months for up to 24 months. Highlights of the study include:

- 84% of patients had sustained success from 12 months to 24 months
- 67% of patients were dry at 24 months
- Of the 38 dry patients at 12 months, 87% maintained their cure at 24 months
- 41% who were considered improved at 12 months were dry at 24 months
- Overall “Incontinence Quality of Life” scores and all subscale scores showed statistically significant improvements
- Patient and physician assessments rated 85% of patients dry or markedly improved at 24 months

“This long term, multicenter study of Macroplastique demonstrated sustained results over two years,” said Dr. Gamal Ghoniem of the Cleveland Clinic Florida and the study’s primary author. “Using widely accepted outcome measures, we confirmed that patients sustained clinical improvements over a prolonged period of time. This positively impacted their quality of life and delayed the need for further treatment. This study

further supports the strong scientific evidence of the effectiveness of Macroplastique for the treatment of stress urinary incontinence,” concluded Dr. Ghoniem.

Macroplastique is an injectable soft-tissue urethral bulking agent for treating adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.

Macroplastique is made up of two parts — a water-soluble gel that is absorbed and removed from the body in urine and a synthetic, rubber-like, silicone elastomer implant material that is permanent and not absorbed by the body. This permanent material causes the bulking effect around the urethra after implantation.

“The study highlighted the durability and efficacy of Macroplastique, which has been the leading urethral bulking agent in Europe for over 18 years,” added Mr. Kaysen. “Macroplastique is being used by urologists across the United States because it offers sustained clinical results. We anticipate the Macroplastique market share to continue to grow as physicians and patients search for lasting solutions for female stress urinary incontinence,” concluded Mr. Kaysen.

In addition to Dr. Ghoniem, the contributing authors included Dr. Jacques Corcos, McGill Urology Associates, Montreal, Canada, Dr. Craig Comiter, University of Arizona, Dr. O. Lenaine Westney, University of Texas, and Dr. Sender Herschorn, University of Toronto, Canada.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent[®] PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence — symptoms often associated with overactive bladder. We also offer Macroplastique[®] Implants, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at <http://uroplasty.com>.

For complete information regarding Macroplastique indications, contraindications, warnings, precautions, instructions for use, storage, adverse reactions and disclaimer of warranties, please refer to the instructions for use brochure available at the Uroplasty website.

Forward-Looking Information

This press release contains forward-looking statements, which reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement

of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, our ability to continue to grow the market share of Macroplastique is subject to a number risks, including the risk that superior technology is developed for the control of adult female urinary incontinency, that competitors with superior personnel and financial resources are able to better market their products, or that physicians select other products because of delivery methods or otherwise.

<p>For Further Information: <u>Uroplasty, Inc.</u> David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, and Treasurer, 952.426.6140</p>	<p>EVC Group Doug Sherk (Investors) 415.896.6820 Chris Gale (Media) 646.201.5431</p>
---	--

###